ATP citrate lyase inhibition can suppress tumor cell growth

Cancer Cell. 2005 Oct;8(4):311-21. doi: 10.1016/j.ccr.2005.09.008.


Many tumors display a high rate of glucose utilization, as evidenced by 18-F-2-deoxyglucose PET imaging. One potential advantage of catabolizing glucose through glycolysis at a rate that exceeds bioenergetic need is that the growing cell can redirect the excess glycolytic end product pyruvate toward lipid synthesis. Such de novo lipid synthesis is necessary for membrane production and lipid-based posttranslational modification of proteins. A key enzyme linking glucose metabolism to lipid synthesis is ATP citrate lyase (ACL), which catalyzes the conversion of citrate to cytosolic acetyl-CoA. ACL inhibition by RNAi or the chemical inhibitor SB-204990 limits in vitro proliferation and survival of tumor cells displaying aerobic glycolysis. The same treatments also reduce in vivo tumor growth and induce differentiation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • ATP Citrate (pro-S)-Lyase / antagonists & inhibitors*
  • Base Sequence
  • Cell Differentiation
  • Cell Division / drug effects*
  • Cell Line, Tumor
  • DNA Primers
  • Enzyme Inhibitors / pharmacology*
  • Homeostasis
  • Humans
  • Lactones / pharmacology
  • Mitochondria / physiology
  • Neoplasms / enzymology
  • Neoplasms / pathology*
  • RNA, Small Interfering / physiology


  • DNA Primers
  • Enzyme Inhibitors
  • Lactones
  • RNA, Small Interfering
  • SB 204990
  • ATP Citrate (pro-S)-Lyase